oxaloacetic acid has been researched along with Disease Models, Animal in 15 studies
Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.
oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxaloacetic acid is an important intermediary in the tricarboxylic acid cycle (TCA cycle) and participates in metabolism and energy production." | 1.48 | Oxaloacetate Ameliorates Chemical Liver Injury via Oxidative Stress Reduction and Enhancement of Bioenergetic Fluxes. ( Han, X; Kuang, Y; Wang, Y; Xu, M; Yang, Q; Zhao, Y, 2018) |
| "Rats that were exposed to permanent middle cerebral artery occlusion (MCAO) and treated with intravenous 250 mg/kg pyruvate had a smaller volume of infarction and reduced brain edema, resulting in an improved neurological outcome and reduced mortality compared to control rats treated with saline." | 1.37 | Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. ( Boyko, M; Gruenbaum, BF; Gruenbaum, SE; Kuts, R; Melamed, I; Ohayon, S; Regev, A; Shapira, Y; Teichberg, VI; Zlotnik, A, 2011) |
| "Propranolol pretreatment blunted the initial decrease in blood glutamate, and thereafter had no effect when compared with control and treatment groups." | 1.36 | The effect of hyperthermia on blood glutamate levels. ( Artru, AA; Dubilet, M; Gruenbaum, SE; Gurevich, B; Leibowitz, A; Ohayon, S; Shaked, G; Shapira, Y; Teichberg, VI; Zlotnik, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Tungtur, SK | 1 |
| Wilkins, HM | 1 |
| Rogers, RS | 1 |
| Badawi, Y | 1 |
| Sage, JM | 1 |
| Agbas, A | 1 |
| Jawdat, O | 1 |
| Barohn, RJ | 1 |
| Swerdlow, RH | 1 |
| Nishimune, H | 1 |
| Kuang, Y | 1 |
| Han, X | 1 |
| Xu, M | 1 |
| Wang, Y | 1 |
| Zhao, Y | 1 |
| Yang, Q | 1 |
| Merlen, G | 1 |
| Raymond, VA | 1 |
| Cassim, S | 1 |
| Lapierre, P | 1 |
| Bilodeau, M | 1 |
| Ruban, A | 3 |
| Mohar, B | 1 |
| Jona, G | 2 |
| Teichberg, VI | 6 |
| Pérez-Mato, M | 1 |
| Ramos-Cabrer, P | 1 |
| Sobrino, T | 1 |
| Blanco, M | 1 |
| Mirelman, D | 1 |
| Menendez, P | 1 |
| Castillo, J | 1 |
| Campos, F | 1 |
| Shibata, K | 1 |
| Inomoto, K | 1 |
| Nakata, C | 1 |
| Fukuwatari, T | 1 |
| Knapp, L | 2 |
| Gellért, L | 1 |
| Kocsis, K | 2 |
| Kis, Z | 3 |
| Farkas, T | 3 |
| Vécsei, L | 3 |
| Toldi, J | 3 |
| Mészáros, J | 1 |
| Malina, KC | 1 |
| Cooper, I | 1 |
| Graubardt, N | 1 |
| Babakin, L | 1 |
| Marosi, M | 1 |
| Fuzik, J | 1 |
| Nagy, D | 1 |
| Rákos, G | 1 |
| Ruban-Matuzani, A | 1 |
| Zlotnik, A | 4 |
| Gurevich, B | 2 |
| Artru, AA | 1 |
| Gruenbaum, SE | 3 |
| Dubilet, M | 1 |
| Leibowitz, A | 2 |
| Shaked, G | 1 |
| Ohayon, S | 3 |
| Shapira, Y | 4 |
| Carvalho, AS | 1 |
| Torres, LB | 1 |
| Persike, DS | 1 |
| Fernandes, MJ | 1 |
| Amado, D | 1 |
| Naffah-Mazzacoratti, Mda G | 1 |
| Cavalheiro, EA | 1 |
| da Silva, AV | 1 |
| Boyko, M | 2 |
| Gruenbaum, BF | 2 |
| Kuts, R | 1 |
| Melamed, I | 2 |
| Regev, A | 1 |
| Brotfain, E | 1 |
| Tkachov, S | 1 |
| Maoz, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors[NCT04592354] | 40 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for oxaloacetic acid and Disease Models, Animal
| Article | Year |
|---|---|
Oxaloacetate treatment preserves motor function in SOD1
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Inflammation; Longevity; Mice; Motor | 2021 |
Oxaloacetate Ameliorates Chemical Liver Injury via Oxidative Stress Reduction and Enhancement of Bioenergetic Fluxes.
Topics: Animals; Antioxidants; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Citric Acid Cyc | 2018 |
Oxaloacetate Protects Rat Liver From Experimental Warm Ischemia/Reperfusion Injury by Improving Cellular Energy Metabolism.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cell Survival; Cells, Cultured; Disease | 2019 |
Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication.
Topics: Animals; Aspartate Aminotransferases; Brain Injuries; Carrier Proteins; Cerebral Cortex; Cholinester | 2014 |
Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia.
Topics: Animals; Aspartate Aminotransferase, Cytoplasmic; Brain; Brain Ischemia; Disease Models, Animal; Hum | 2014 |
Pantothenic acid deficiency may increase the urinary excretion of 2-oxo acids and nicotinamide catabolites in rats.
Topics: Adipates; Animals; Disease Models, Animal; Ketoglutaric Acids; Male; Niacinamide; Oxaloacetic Acid; | 2013 |
Neuroprotective effect of oxaloacetate in a focal brain ischemic model in the rat.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Male; Neuroprotective Agents; Oxaloacetic Acid; Rat | 2015 |
Acetyl-L-carnitine and oxaloacetate in post-treatment against LTP impairment in a rat ischemia model. An in vitro electrophysiological study.
Topics: Acetylcarnitine; Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; | 2015 |
Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment.
Topics: Amyotrophic Lateral Sclerosis; Animals; Aspartate Aminotransferases; Disease Models, Animal; Drug Th | 2015 |
Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Post | 2009 |
The effect of hyperthermia on blood glutamate levels.
Topics: Adrenergic beta-Antagonists; Animals; Autonomic Nervous System; Bicarbonates; Blood Glucose; Body Te | 2010 |
Neuroprotective effect of pyruvate and oxaloacetate during pilocarpine induced status epilepticus in rats.
Topics: Animals; Disease Models, Animal; Male; Nerve Degeneration; Neuroprotective Agents; Oxaloacetic Acid; | 2011 |
Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke.
Topics: Animals; Aspartate Aminotransferases; Brain Edema; Brain Infarction; Disease Models, Animal; Dose-Re | 2011 |
The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Disease Models, Animal; Glutamic Acid; Male; Nervous Sys | 2012 |
Brain neuroprotection by scavenging blood glutamate.
Topics: Animals; Aspartate Aminotransferase, Cytoplasmic; Brain; Brain Injuries; Disease Models, Animal; Dos | 2007 |